Maithreyi Chappidi
Neurology · Saint Louis, MONPI 1710474473
Payments from drug & device makers
Across 37 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$221
- E.r. Squibb & Sons, L.L.C.$217
- Mallinckrodt Hospital Products Inc.$161
- AstraZeneca$103
- Sanofi$67
- Biohaven Pharmaceuticals, Inc.$55
- plus $258 from 11 others
Across 14 payments — averaging $172.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
What the payments were for
- Food & beverage$1,081100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 6 | $221 |
| E.r. Squibb & Sons, L.L.C. | 2 | $217 |
| Mallinckrodt Hospital Products Inc. | 3 | $161 |
| AstraZeneca | 6 | $103 |
| Sanofi | 3 | $67 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Pfizer | 3 | $46 |
| Biogen | 2 | $33 |
| Merz Pharmaceuticals, LLC | 1 | $32 |
| Bristol Myers Squibb | 1 | $23 |
| SK Life Science, Inc. | 1 | $23 |
| Amylyx Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,081 in reported general payments places this provider in the 45th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FingolimodFingolimod Hcl | 22 | $88,726 |
| Baclofen | 25 | $857 |
| Duloxetine Hcl | 21 | $834 |
| Gabapentin | 29 | $338 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $320 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Louis
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Gregory WuSaint Louis$5.7M
- Barry SingerSaint Louis$3.3M
- Mark TullmanSaint Louis$2.3M
- Suzanne SchindlerSaint Louis$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.